Data Sharing? The Case for Blockchain at the Global Convergence of Healthcare, Life sciences, and Consumer Markets

Main Article Content

Ron Ribitzky Uli Broedl Chrissa McFarlane Kevin A. Clauson

Abstract

(no abstract or summary available)

Downloads

Download data is not yet available.

Article Details

How to Cite
Ribitzky, R., Broedl, U., McFarlane, C., & Clauson, K. (2018). Data Sharing? The Case for Blockchain at the Global Convergence of Healthcare, Life sciences, and Consumer Markets. Blockchain in Healthcare Today. Retrieved from https://blockchainhealthcaretoday.com/index.php/journal/article/view/78
Section
Track: Knowledge and Leadership
Author Biographies

Ron Ribitzky, R&D Ribitzky, Founder & CEO

https://RDRibitzky.com

An entrepreneurial driver and enabler of pragmatic innovation, Dr. Ribitzky is a highly accomplished Physician executive with 30 years of cross-functional experience in Healthcare IT, Life-Sciences Informatics, and Precision Medicine. 

Dr. Ribitzky worked for and with global leading brands and world-class organizations in the private and public-sector, R&D, and academia in the US and 23 developed and developing economy countries. As Founder and CEO of R&D Ribitzky he serves investors, entrepreneurs, and economic buyers of innovative technology solutions worldwide. 

Dr. Ribitzky has broad and deep hands-on, managerial, and scientific technology expertise that includes AI, analytics, UX prototyping, blockchain, semantic services, and NLP, among other.

A sought after thought leader and author of numerous publications, Dr. Ribitzky presented and led workshops on technology innovation and practice in industry events, public sector, and academia around the world. He served as an Expert Reviewer and Mentor for HIMSS18’s Precision Medicine and Genomics track; moderated National Science Foundation’s international workshop on Personalized Medicine, and is the Principal Author and Chief Editor of the book “Knowledge Mining and Bioinformatics Techniques to Advance Personalized Diagnostics and Therapeutics: The Case for White Space R&D” that followed.

Frost & Sullivan adopted Dr. Ribitzky’s Blockchain Roadmap for its ‘Blockchain Technology in Global Healthcare, 2017–2025’ report. He collaborated with IDC on the Healthcare track at the ‘Blockchain for Business & IT Leaders’ conference. Dr. Ribitzky is a member of HIMSS’ Blockchain Work Group and the Advisory Board of ARNA Genomics and BitMed. He was quoted on various Blockchain related trends in Healthcare and Genomics by GenomeWeb and San Diego Business Journal.

Previously, Dr. Ribitzky co-founded SPH Analytics where he also served as SVP Product Management and SVP Technology Services. He has held leadership positions with multiple companies, serving as a Senior Healthcare Strategist with Intel, where he won Intel Award for Healthcare IT Value Model and two KUDOS awards from team members for Customer Orientation, Results Orientation, Discipline, and Risk Taking; and CIO at the University of Massachusetts Medical Center, among other. 

While with Eclipsys, an EMR company, Dr. Ribitzky led teams spanning Advanced Research, Emerging Technologies, Demo Systems Group, Prototype Development, and Medical Sales Support. He and his team won multiple Chairman Awards and Sales recognition for exceptional accomplishments, entrepreneurship and teamwork.

A seasoned board member, Dr. Ribitzky has held roles with the NSF Center for Intelligent Information Retrieval, Collexis, Microsoft R&D Personal Health Strategic Core Business, Asklepios Future Hospital Architecture Board, Applied Computing Systems Institute of Massachusetts (a UMass Technology Transfer affiliate), HIMSS Electronic Health Record Usability Workgroup Leadership Council, and Gartner Healthcare View Executive Steering Committee. 

Dr. Ribitzky held academic appointments at Harvard, UMass, Emory, Rwanda’s KHI / KIST, and other.

Dr. Ribitzky obtained his MD from Tel Aviv University and has earned numerous Certifications including Strategy & Action in the Information Processing Industry – Intel Management & Leadership Development at Stanford University’s Graduate School of Business; Finance and Accounting for Non-Financial Managers from Georgia Institute of Technology, and Health Systems Management Seminar at Harvard University’s School of Public Health as well as Medical Decision Making, Knowledge Engineering, and Project Management. 

Uli Broedl, Boehringer Ingelheim, Canada, Medical Director and Vice President of Medical and Regulatory Affairs

https://boehringer-ingelheim.ca/en

Dr. Uli Broedl, MD, is Medical Director and Vice President of Medical and Regulatory Affairs at Boehringer Ingelheim Canada since January 2017. He is the medical representative of the company’s executive leadership team and oversees all aspects of clinical operations, clinical development, medical affairs, regulatory affairs, drug safety and clinical quality management. Dr. Broedl is passionate about fostering innovation
and new disruptive technologies that hold promise to improve patient care (e.g., blockchain technology in healthcare).

After having joined Boehringer Ingelheim in 2009 as global Deputy Therapeutic Area Head Metabolism, Dr. Broedl was responsible for building a Late Clinical Development team that drove the global registrations of various glucose-lowering medications in patients with type 2 diabetes mellitus.

Dr. Broedl is adjunct Professor of Medicine at the University of Munich, Germany, and holds a Doctorate of Medicine degree from the University of Munich. He completed a Postdoctoral Fellowship in Dr. Daniel J. Rader ́s lab, Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, and completed his
training in Internal Medicine, Endocrinology and Metabolism at the Medical Center of the University of Munich.

Chrissa McFarlane, Patientory, Founder/CEO

https://patientory.com/

Chrissa McFarlane is the CEO of Patientory, a global currency and population health management service that regulates and secures patient data, Named as one of the top women “leaving their mark on the medtech field” by Becker’s Hospital Review, Chrissa launched Patientory in December 2015 after seeing the need in the market for a more personalized and secure population health management solution.

Chrissa exudes creativity and is a high-performing strategic thinker and excellent team-builder. She’s an entrepreneur with a passion for creating cutting-edge healthcare products that transform the face of healthcare delivery in the US and abroad. She brings over 10 years in the healthcare industry conducting research and managing teams. She holds notable international published research in healthcare and has helped create breakthrough digital health companies that have provided services to companies such as Tumblr, Blue Apron, Casper and Meetup. 

Her passion for health care began as early as high school, where she conducted microbiology research at the Albert Einstein College of Medicine and won top honors at the Otto Burgdorf Research Competition. Later at Cornell University, Chrissa worked with organizations such as the United States Department of Agriculture-Robert Holey Center for Agriculture and Health and Cayuga Medical Center. After teaching Math and Science for a year in an underserved community inside the Atlanta Public School system, Chrissa decided to pursue business school. She holds a Bachelor of Arts, cum laude from Cornell, and a Masters in Management from the Wake Forest University School of Business. 

Chrissa resides in Atlanta and Tweets at @ChrissaTanelia.

Kevin A. Clauson, Lipscomb University, Associate Professor, College of Pharmacy & Health Sciences

https://lipscomb.edu/pharmacy/bio/detail/3233

Dr. Clauson is an associate professor at the Lipscomb University College of Pharmacy & Health Sciences in Nashville, TN, USA. Dr. Clauson previously served as founding director of the first World Health Organization Collaborating Center to prioritize mobile health (mHealth) initiatives in its work plan.

Recently, he helped lead the initiative for Lipscomb University to become the first academic organization to join Hashed Health’s consortium. His previous blockchain efforts include roles at Stanford Blockchain Disrupt, White House Precision Medicine Initiative workshop, Distributed:Health, and IEEE Blockchain Clinical Trials.

Dr. Clauson’s research appears in peer-reviewed journals, books, and other media and has generated coverage by the New York Times, Forbes.com, and BBC Radio. Dr. Clauson received his Doctor of Pharmacy from the University of Tennessee, Memphis, and completed a Research Fellowship at the University of Missouri, Kansas City.